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Abstract
AIM
To investigate management of patients who develop 
ipilimumab-mediated enterocolitis, including association 
of endoscopic findings with steroid-refractory symptoms 
and utility of infliximab as second-line therapy.
METHODS
We retrospectively reviewed all patients at our center 
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with metastatic melanoma who were treated with 
ipilimumab between March 2011 and May 2014. All 
patients received a standard regimen of intravenous 
ipilimumab 3 mg/kg every 3 wk for four doses or 
until therapy was stopped due to toxicity or disease 
progression. Basic demographic and clinical data were 
collected on all patients. For patients who developed 
grade 2 or worse diarrhea (increase of 4 bowel 
movements per day), additional data were collected 
regarding details of gastrointestinal symptoms, 
endoscopic findings and treatment course. Descriptive 
statistics were used.
RESULTS
A total of 114 patients were treated with ipilimumab 
during the study period and all were included. Sixteen 
patients (14%) developed ≥ grade 2 diarrhea. All 
patients were treated with high-dose corticosteroids 
(1-2 mg/kg prednisone daily or equivalent). Nine of 
16 patients (56%) had ongoing diarrhea despite high-
dose steroids. Steroid-refractory patients received 
one dose of intravenous infliximab at 5 mg/kg, and 
all but one had brisk resolution of diarrhea. Fourteen 
of the patients underwent either colonoscopy or 
sigmoidoscopy with variable endoscopic findings, 
ranging from mild erythema to colonic ulcers. Among 
8 patients with ulcers demonstrated by sigmoidoscopy 
or colonoscopy, 7 patients (88%) developed steroid-
refractory symptoms requiring infliximab. With a median 
follow-up of 264 d, no major adverse events associated 
with prednisone or infliximab were reported.
CONCLUSION
In patients with ipilimumab-mediated enterocolitis, the 
presence of colonic ulcers on endoscopy was associated 
with a steroid-refractory course.
Key words: Ipilimumab; Melanoma; Enterocolitis; 
Colitis; Infliximab; Corticosteroid; Colonic ulcer
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Core tip: Immune-mediated enterocolitis is a common 
toxicity of ipilimumab therapy for melanoma. Infliximab 
is often needed as a second line therapy in steroid 
refractory cases. Our findings suggest that colonic 
ulcers seen on lower gastrointestinal endoscopy may 
predict a steroid refractory disease course. This would 
support a role for endoscopy in select cases, and 
suggest that early initiation of infliximab therapy may 
be appropriate in patients with colonic ulceration. 
These results require further exploration in larger 
patient cohorts. 
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INTRODUCTION
Ipilimumab (YervoyTM, Bristol-Myers Squibb, Princeton, 
NJ, United States) is a first-in-class monoclonal 
antibody that blocks the immune regulatory molecule 
cytotoxic T-lymphocyte antigen-4 (CTLA-4), resulting 
in T-cell activation. It was approved by the United 
States Food and Drug Administration (FDA) in 2011 
after two phase 3 studies demonstrated a survival 
benefit in patients with advanced melanoma[1-5]. It 
is now being tested in clinical trials in patients with a 
variety of tumor types.
Ipilimumab administration is associated with nume-
rous immune-related adverse effects (irAE) including 
enterocolitis, hepatitis, hypophysitis, dermatitis, as well 
as several others[1,4,6]. Enterocolitis is among the most 
common toxicities, manifesting as diarrhea, abdominal 
pain, nausea or hematochezia. The overall incidence of 
any diarrhea (grade 1 or higher) has been reported as 
31%-43% in various studies[1,3-5,7]. 
Immune-mediated diarrhea is typically treated 
based on severity. Anti-diarrheal medications such 
as loperamide are often used for patients with mild 
symptoms. Corticosteroids are generally administered 
in cases of moderate to severe diarrhea. In some 
steroid-refractory cases, the tumor necrosis factor 
alpha inhibitor infliximab has demonstrated efficacy 
in alleviating symptoms[8-10]. As more patients receive 
ipilimumab and similar immune therapies (such as anti-
PD-1 therapies), gastroenterologists are increasingly 
being asked to assist in the management of patients 
immune-mediated enterocolitis. Questions remain 
regarding the role of endoscopy, and the optimal timing 
of infliximab administration. 
To better understand the clinical features and treat-
ment approaches to ipilimumab-mediated enterocolitis, 
we examined our single-center experience with post-
FDA approval ipilimumab therapy in a large cohort of 
patients with metastatic melanoma.
MATERIALS AND METHODS
We conducted a retrospective study of all patients 
treated with ipilimumab for advanced melanoma from 
March 2011 to May 2014 at our institution. All patients 
were treated with a standard regimen of 3 mg/kg of 
intravenous ipilimumab administered every 3 wk for 
4 total doses or until development of drug toxicity, 
disease progression or death. Diarrhea was graded 
based on the National Cancer Institute’s (NCI’s) Common 
Terminology Criteria for Adverse Events (CTCAE), 
version 4.0: (1) Grade 1 - increase of < 4 stools per 
day over baseline; (2) Grade 2 - increase of 4-6 stools 
per day; (3) Grade 3 - increase of > 6 stools per day, 
or incontinence or hospitalization; (4) Grade 4 - life-
threatening consequences; and (5) Grade 5 - death.
Using the electronic medical record, demographic 
and clinical data were collected on all patients, including 
age, sex, peripheral white blood cell count, lymphocyte 
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count, neutrophil count, platelet count, information 
on melanoma treatment response, and mortality. 
Charts for all patients were reviewed to determine 
which patients developed grade 2 or worse diarrhea. 
For patients who developed at least grade 2 diarrhea, 
additional data were collected, including details of 
diarrhea, other gastrointestinal symptoms, endoscopy 
results, pathology results, therapy for diarrhea, and 
response to therapy. Descriptive statistics were used to 
evaluate the data. Missing data variables were omitted 
from the analysis (pairwise deletion). 
The study was approved by the Institutional Review 
Board of the Johns Hopkins University.
RESULTS
Patient characteristics
A total of 114 patients were treated with ipilimumab 
for metastatic melanoma during the study period; 
all were included in the study. Baseline demographic 
and laboratory characteristics were similar between 
patients who developed grade 2 (increase of 4 bowel 
movements per day) or worse diarrhea and those 
who did not (Table 1). A total of 16 patients (14%) 
developed grade 2 or worse diarrhea. 
Out of 114 total patients, baseline CBC and di-
fferential data were missing for 2 patients. One 
patient moved to another city only 21 d after starting 
ipilimumab therapy and no additional follow-up data 
were available regarding her condition. All other data 
were available for analysis.
Clinical features
Sixteen patients developed ipilimumab-mediated 
enterocolitis. Clinical features and treatment outcomes 
are shown in Table 2. Onset of diarrhea occurred after 
a median of 2 doses of ipilimumab and after a median 
of 33 d from the first dose of ipilimumab (range 5-94 d). 
Patients had a median of 6 bowel movements per day 
with stool being described as watery and non-bloody 
in most patients; one patient reported trace amounts 
of blood in the stool initially. Most patients (63%) 
reported abdominal pain with a cramping character, 
while a minority of patients had fever, anorexia, or 
nausea.
Workup and endoscopic findings
Standard medical workup included polymerase chain 
reaction stool test for Clostridium difficile toxin and 
stool culture for routine enteric pathogens (including 
Salmonella, Campylobacter, Shigella, and Escherichia 
coli), which were negative in all patients. Testing for 
celiac disease was not routinely performed. All but two 
patients underwent endoscopic evaluation with either 
flexible sigmoidoscopy (4 patients) or full colonoscopy 
(10 patients). Endoscopic appearance was variable: 
some patients had only mild edema and erythema of 
the mucosa (6 patients), while others had ulcers in the 
colon (8 patients). All 10 patients who underwent a full 
colonoscopy had at least patches of abnormal mucosa 
in the right and left colon. Histologic analysis revealed 
crypt apoptosis, crypt abscesses, and/or cryptitis in 12 
of 14 patients (86%). 
Treatment of enterocolitis
Patients with grade 2 diarrhea were treated with high-
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Table 1  Baseline characteristics of patients
Ipilimumab induced enterocolitis Ipilimumab without enterocolitis
Demographics
   Total number of patients 16 98
   Mean age in years 63 61
   Female sex, n (%) 8 (50) 28 (29)
Laboratory characteristics prior to ipilimumab
   Mean white blood cell count, cells/cu. mm (range) 6720 (3510-17100) 7530 (1080-25800)
      Reference range 4500-11000 cells/cu. mm
   Mean lymphocyte count, cells per cu. mm (range) 1570 (592-4610) 1440 (97-4420)
      Reference range 1150-4800 cells/cu. mm
   Mean neutrophil count, cells per cu. mm (range) 4350 (2040-11610) 5200 (668-23500)
      Reference range 1800-7000 cells/cu. mm
Table 2  Clinical features and treatment of 16 patients with 
ipilimumab-mediated enterocolitis n  (%)
Onset of diarrhea
   After 1 dose of ipilimumab 3 (19)
   After 2 doses of ipilimumab 7 (43)
   After 3 doses of ipilimumab 3 (19)
   After 4 doses of ipilimumab 3 (19)
Diarrhea details
   Number of bowel movements/day, median (range) 6 (5-12)
   Grade 2 diarrhea 9 (56)
   Grade 3 diarrhea 7 (44)
   Grade 4/5 diarrhea 0
Associated symptoms
   Abdominal pain 10 (63)
   Nausea or vomiting 3 (19)
   Fever 2 (13)
   Anorexia 2 (13)
Endoscopic findings
   Mucosal erythema, edema, or erosions only 6 (43)
   Ulcers 8 (57)
Treatment of diarrhea
   High dose corticosteroids 16 (100)
   Infliximab 9 (56)
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A case of Ipilimumab-mediated enteritis
One patient developed severe diarrhea with 12 bowel 
movements per day only 8 d after her first dose 
of ipilimumab. She presented to the hospital with 
diarrhea and fevers 4 d after the onset of symptoms. A 
CT scan of the abdomen and pelvis revealed moderate 
diffuse thickening of the small bowel, which was 
not present on an abdominal CT scan 1 wk prior to 
receiving ipilimumab. Sigmoidoscopy performed the 
following day showed normal colonic mucosa and no 
evidence of colitis on histology. She was diagnosed 
with ipilimumab-mediated enteritis but did not improve 
with prednisone 80mg daily. After 2.5 wk of prednisone 
therapy, she was given a dose of infliximab with reso-
lution of her diarrhea within 7 d.
Completion of Ipilimumab course
Three patients had already received all four doses of 
ipilimumab prior to developing enterocolitis. Four other 
patients were ultimately able to resume ipilimumab 
and complete the full 4 doses of therapy (2 patients 
who only received steroids, and 2 patients who received 
steroids and infliximab). Hence a total of 7 of 16 (44%) 
patients ultimately completed all 4 doses of ipilimumab 
therapy. 
Follow-up and adverse effects
Follow-up was available on patients for a median of 264 
d (range 17-1055) from the date of first ipilimumab 
dose corticosteroids (1-2 mg/kg prednisone per day 
or equivalent). Most patients were also treated with 
loperamide at the onset of symptoms. Ipilimumab 
therapy was suspended at the onset of grade ≥ 2 
diarrhea.
In 7 patients (44%), gastrointestinal symptoms 
resolved after administration of high-dose corticos-
teroids. Nine patients (56%) experienced ongoing 
diarrhea despite steroids and were treated with a 
single dose of 5 mg/kg of intravenous infliximab. 
Eight patients (89%) reported improvement of 
gastrointestinal symptoms within 1-2 wk of infliximab 
therapy. One patient had ongoing diarrheal symptoms 
after one dose of infliximab. Prednisone was weaned 
off, but he continued to have symptoms. He was 
treated with a second dose of infliximab 9 wk after the 
first dose with improvement in diarrhea. 
Seven of 8 patients (88%) who had mucosal 
ulceration on sigmoidoscopy or colonoscopy developed 
steroid refractory diarrhea requiring infliximab, 
whereas only 2 of 6 patients without colonic ulcerations 
required infliximab (positive likelihood ratio = 3.89, 
95%CI: 0.65-23.2; negative likelihood ratio = 0.28, 
95%CI: 0.08-1.02). Also of note, the one patient who 
required 2 doses of infliximab had multiple long ulcers 
(approximately 1 centimeter ulcers) on colonoscopy. 
See Figure 1 for summary of endoscopic findings and 
treatment outcomes. Grade of diarrhea did not appear 
to correlate with steroid refractory symptoms.
A B
C D
Figure 1  Sample endoscopic images from patients with ipilimumab-mediated enterocolitis. A: A large, punched-out ulcer in the center of the image; B: A linear 
colonic ulcer; C: A segment of mild, diffuse colitis with punctate areas of erythema and colitis; D: Patchy, mild erythema. Patients from A and B had a steroid refractory 
course and required infliximab, while patients from C and D had steroid responsive symptoms.
Jain A et al . Colon ulcers in ipilimumab enterocolitis
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infusion to last oncology follow-up or death. One patient 
suffered labile mood while on high-dose prednisone and 
another patient reported hyperglycemia and vaginal 
candidiasis while on high-dose prednisone. No other 
adverse events, including other infections or bowel 
perforation, were reported through the follow-up period.
DISCUSSION
Diarrhea and enterocolitis are among the most 
common immune-related adverse events associated 
with ipilimumab therapy. With the increasing use of 
immune-based therapies for patients with various 
cancer types, gastroenterologists are likely to see a 
growing burden of immune-mediated gastrointestinal 
toxicities. In the present analysis, we report a single 
center experience of 114 patients with metastatic 
melanoma who presented with ipilimumab-mediated 
enterocolitis. Overall, 14% of patients developed grade 
≥ 2 diarrhea. More than half of those patients had 
steroid-refractory symptoms requiring treatment with 
infliximab. Interestingly, 8 of 9 patients (88%) with 
ulcers found on colonoscopy/sigmoidoscopy experienced 
a steroid-refractory course requiring infliximab (Figure 
1). 
While the cohort size in our study is relatively 
small, this potential association deserves further investi-
gation. If validated, this finding could have important 
implications in the management of some patients with 
ipilimumab-mediated enterocolitis. Prompt evaluation 
with colonoscopy/sigmoidoscopy may provide 
prognostic information, allowing clinicians to consider 
initiation of infliximab therapy in patients whose 
symptoms do not rapidly respond to corticosteroids 
and who are found to have mucosal ulceration.
Prior studies have estimated incidence of ipili-
mumab-mediated diarrhea (any grade) to be in the 
range of 14%-29%[1,3,10,11]. In our cohort, we observed 
≥ grade 2 and grade 3 diarrhea in 14% and 6% of 
patients, respectively, which is consistent with previous 
reports[1,4,5,10,12].
Initial experience with ipilimumab in the clinical trial 
setting seemed to indicate that steroid-refractory colitis 
was rare. For example, in a landmark phase 3 trial, 
only 4 of 179 (2%) patients with diarrhea or colitis 
required treatment with infliximab[1]. An earlier phase 
2 study by Beck and colleagues reported refractory 
enterocolitis requiring infliximab in only 4 of 41 (10%) 
patients with enterocolitis[11]. 
By contrast, more contemporary experience with 
ipilimumab in the post-FDA approval era has provided 
evidence that steroid-refractory enterocolitis may 
be more common than initially thought. A large, re-
trospective, single-center review recently reported 
steroid-refractory symptoms in approximately 30% 
of patients with a serious immune-related adverse 
event[10]. Another recent study reported steroid-
refractory symptoms in 26% of patients with ipili-
mumab-induced colitis. In our study, 9 of 16 (56%) 
patients had steroid-refractory symptoms requiring 
infliximab rescue therapy.
Of those, 8 patients experienced symptom im-
provement after a single dose of infliximab. One 
patient experienced lingering symptoms requiring 
a second dose of infliximab. This is consistent with 
previously published series, which have reported 
efficacy rates of infliximab in treating steroid-refractory 
ipilimumab-induced diarrhea between 72%-100%[8-10]. 
Administration of steroids and infliximab does not 
seem to adversely affect the anti-tumor response 
of immune based therapy. A recent report from the 
Memorial Sloan Kettering group indicates that the use 
of immune suppressive medications for the treatment 
of immune-related adverse events did not adversely 
impact overall survival or time to change in oncologic 
therapy in patients with melanoma[10].
The mechanism of ipilimumab-mediated entero-
colitis has not been precisely elucidated. Indeed, with 
the increase availability of novel biologic agents, there 
is a growing recognition of the spectrum biologic 
drug-mediated enterocolitis. Each of these drugs may 
affect different lymphocyte targets of the gut mucosal 
immune system leading to enterocolitis. Ipilimumab 
specifically targets the inhibitory T-cell surface protein 
CTLA-4. Prior investigation has shown that T-cell 
depletion does not appear to be a feature in the 
pathogenesis of ipilimumab-mediated enterocolitis[7]. 
Berman and colleagues posit that ipilimumab results 
in dysregulation of mucosal immunity, evidenced 
by alterations in antibody levels to various microbial 
antigens and elevated fecal calprotectin levels[13]. 
Further understanding of ipilimumab and other biologic-
mediated enterocolitides may have broader implications 
for understanding other inflammatory gastrointestinal 
disease states.
In conclusion, although our study was limited by its 
retrospective design, small cohort size and the fact that 
all patients were treated at a single tertiary center, our 
findings raise the possibility that the presence of colonic 
ulcers in patients with ipilimumab-mediated enterocolitis 
may predict a steroid refractory course. These results 
should be explored in larger patient cohorts in order to 
elucidate the utility of endoscopic evaluation and early 
administration of infliximab. 
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management of ipiliumumab-mediated enterocolitis are evolving. In particular, 
the management of corticosteroid refractory cases is still being understood. As 
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corticosteroids, with growing evidence to support the use of infliximab in 
refractory cases. There are no well-known predictors of steroid refractory 
disease course and the role of endoscopy in such cases is unclear. In this 
report, the authors report on a large cohort of patients treated with ipilimumab 
with particular focus on the role of endoscopic findings.
Innovations and breakthroughs
In the present manuscript, the authors present the novel finding that severity 
of endoscopic findings, namely colonic ulcers, could be a predictor of steroid 
refractory disease course in patients with ipilimumab-mediated enterocolitis.
Applications
This manuscript would support a role for colonoscopy or sigmoidoscopy in 
patients with ipilimumab-mediated enterocolitis. Patients with worse endoscopic 
findings, such as colonic ulcers, may be more likely to have refractory disease 
course and this may be a reason to offer earlier rescue therapy, such as 
infliximab, in such patients. 
Terminology
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an immune regulatory molecule 
found on the surface of T-lymphocytes. CTLA-4 is the target of ipilimumab and 
activation of CTLA-4 results in T-cell activation.
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